Answers are grounded in this paper and cite their sources.
Correspondence discusses fibroblast heterogeneity and PAK2 activation in idiopathic pulmonary fibrosis, highlighting therapeutic potential.
Extract We have read the correspondence from M. Sun and co-workers with great interest and appreciate their engagement with our study, which combined spatial transcriptomics and single-cell RNA sequencing to resolve fibroblast heterogeneity across fibroblastic foci (FF) and dense fibrosis (DF) in idiopathic pulmonary fibrosis (IPF), regions characterised by p21-activated kinase 2 (PAK2) activation as a potential therapeutic target [1]. We would like to offer a few comments in response to their thoughtful remarks.
No takes yet. Share an insight, caveat, or question.
Hirano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: